4:30pm Friday 15th August 2008
By Andrew Smith
BIOTECH firm Oxford BioMedica has rejected a second takeover approach by an American firm.
Directors at the company based on the Oxford Science Park originally vetoed a move by GeneThera in July and have now blocked a second attempt which would have involved an all share offer.
In a statement, the Biomedica board said: "This unsolicited approach is not credible and is not in the interests of shareholders."
The revelation follows the news that a trial of Oxford Biomedica's kidney cancer vaccine Trovax would not meet its goal.
The company's shares slumped as a result to 7.5p from a high of more than 50p. Yesterday frithey rallied to more than 10.5p
© Copyright 2001-2010 Newsquest Media Group
http://www.heraldseries.co.uk